NASDAQ$IRON
Disc Medicine Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Disc Medicine reported financial results for the second quarter ending June 30, 2023 and provided a business update.
Disc Medicine reported a net loss of $15.9 million for the second quarter of 2023. The company's cash and cash equivalents were $377.6 million as of June 30, 2023, which are expected to fund operational plans well into 2026.
- Presented positive initial safety and efficacy data from BEACON trial at the European Hematology Association (EHA) Congress in June 2023.
- Initiated phase 1/2 study of bitopertin in patients with Diamond-Blackfan Anemia who have failed corticosteroid treatment.
- Enrolling patients in two separate Phase 1b/2 studies for DISC-0974.
- Strengthened financial position through $158 million upsized public offering; ended Q2 with approximately $378 million in cash that is expected to fund operations well into 2026.
Headline financials
Revenue & EPS history
Disc Medicine · Revenue · Quarterly
$0
Forward guidance
Disc Medicine anticipates continued progress across its portfolio and expects to provide updated results from BEACON and other studies by the end of the year. They believe they will have capital to fund Disc well into 2026.
Tailwinds
- Positive initial data from BEACON study.
- Completion of upsized public offering.
- Advancing bitopertin into late-stage development.
- Continued enrollment for AURORA study.
- Plans to initiate a Phase 1 study in healthy volunteers during the second half of 2023 for MWTX-003.
Headwinds
- Difficulty in predicting the time and cost of development of product candidates.
- Risk that the results of preclinical studies and clinical trials may not be predictive of future results.
- The adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials.
- Timing of the availability of data from Disc’s clinical trials
- Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2023
-0.4%
Avg return
Earnings day
-1.7%
Avg return
5 days after
+3.9%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+14.6%
Q3 2021
Best reaction
-12.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +1.3% | -3.8% | -10.2% | |
| Q3 2025 | -1.6% | -2.5% | +5.6% | |
| Q2 2025 | -3.4% | +0.1% | +3.0% | |
| Q1 2025 | +2.3% | +3.8% | +14.1% | |
| Q4 2024 | +0.1% | +1.6% | -3.9% | |
| Q3 2024 | -5.3% | -10.7% | -3.5% | |
| Q1 2024 | +3.5% | +8.5% | +33.3% | |
| Q4 2023 | -8.7% | -9.2% | -56.8% | |
| Q3 2023 | +1.7% | +8.1% | +27.8% | |
| Q2 2023 | +0.3% | +1.9% | -1.2% | |
| Q1 2023 | +0.6% | +1.8% | +47.6% | |
| Q4 2022 | -0.6% | +0.7% | +48.4% | |
| Q3 2022 | -0.6% | -4.7% | -2.4% | |
| Q2 2022 | -12.4% | -10.9% | -31.8% | |
| Q1 2022 | +3.6% | +10.1% | +8.6% | |
| Q4 2021 | -3.2% | -7.7% | -11.0% | |
| Q3 2021 | +14.6% | -5.6% | -12.6% | |
| Q2 2021 | +0.2% | -12.8% | +15.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro